Trial Profile
A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving Cervarix or Gardasil Human Papillomavirus Vaccines.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- 31 Jan 2022 Results of an analysis assessing the breadth, magnitude and durability of the vaccine-induced antibody response against vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) type antigens up to 7 years following vaccination of 12-15 year old girls in a three dose schedule and contrast these data with the levels of antibody typically seen in natural infection published in the Vaccine
- 27 Mar 2019 Results evaluating the durability of vaccine and non-vaccine antibody responses of Cervarix or Gardasil vaccine published in the Vaccine
- 25 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.